FDA Brief

Warning letters Drugs

FDA warning letter to

Tianjin Healthcare Medical Technology Co., Ltd.

High riskIssued Oct 29Posted Nov 10Center for Drug Evaluation and Research (CDER)

Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

What happened

FDA reviewed import records and found multiple shipments of active pharmaceutical ingredients (APIs, the drug ingredients that go into a finished medicine) made by Tianjin Healthcare Medical Technology Co., Ltd. (THM) and intended for pharmacy compounding in the US. FDA emailed records requests on June 17, 2026 to the contact address in the firm's registration file; the firm replied on June 24 that it would stop making the products for the US and would not send the records, and refused again after a June 25 follow-up. No inspection took place; FDA placed all drugs from the firm on Import Alert 66-79 on August 25, 2026.

What FDA found

  1. The firm refused to give FDA the records it asked for by email, even after FDA said the shipped ingredients were still within expiry.

    Section 704(a)(4) and section 301(e) of the FD&C Act, 21 U.S.C. 374(a)(4), 331(e)
  2. After saying it would stop making drugs for the US, the firm did not formally update its FDA registration and drug listings to show the change.

    21 CFR 207.29(a)(3)

What FDA wants

Send a written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receiving the letter, marked with FEI 3015495180 and ATTN: Marva Taylor. The firm may also ask FDA to schedule an inspection, and if it truly has stopped supplying the US market it must formally update its registration.

Who should pay attention

  • pharmacy compounders and compounding pharmacies buying APIs from overseas
  • US brands and repackagers sourcing APIs from Chinese manufacturers
  • quality and regulatory teams tracking import alerts and supplier records

This is a summary. Read the original letter on fda.gov.